Mineralys CMO receives stock, option grants

Q: What equity awards did MLYS Chief Medical Officer James J. Ferguson III receive on 2026-08-10?

James J. Ferguson III received 102,400 RSUs of common stock and a stock option for 135,000 shares at an exercise price of $27.38 per share as part of his equity compensation.

Q: How do the 102,400 RSUs granted to the MLYS Chief Medical Officer vest?

The 102,400 RSUs vest over four years, with 1/4 of the shares vesting on each one-year anniversary of the grant date, contingent on the vesting conditions described in the award.

Q: What are the terms of the 135,000-share stock option granted by MLYS?

The stock option covers 135,000 shares of common stock at an exercise price of $27.38 per share, vesting 25% on the first anniversary and the remaining shares in 36 substantially equal monthly installments, expiring on 2036-08-10.

Q: Were the MLYS equity awards to the Chief Medical Officer granted for cash consideration?

The RSUs were granted for no additional cash consideration, each representing a contingent right to receive one share of common stock upon vesting; the stock option has an exercise price of $27.38 per share when exercised.

Q: What is the expiration date of the MLYS stock option granted to the Chief Medical Officer?

The stock option granted to James J. Ferguson III for 135,000 shares of Mineralys Therapeutics common stock carries an expiration date of 2036-08-10, subject to the vesting and other plan terms.

Mineralys Therapeutics, Inc. reported that Chief Medical Officer James J. Ferguson III received equity-based compensation on 2026-08-10.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Mineralys Therapeutics, Inc. reported that Chief Medical Officer James J. Ferguson III received equity-based compensation on 2026-08-10. He was granted 102,400 shares of common stock in the form of Restricted Stock Units (RSUs), vesting in four equal annual installments starting on the first anniversary of the grant date. He also received a stock option for 135,000 shares of common stock at an exercise price of $27.38 per share, vesting 25% on the first anniversary and the remainder in 36 substantially equal monthly installments, and expiring on 2036-08-10. Following these awards, his reported direct holdings related to these grants are 102,400 common shares and options for 135,000 shares.

Insider Trade Summary

Grant/Award: 237,400 shares

Grant/Award 2 txns

Insider Ferguson James J. III

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option ^F2	135,000	$0.00	$0.00
Grant/Award	Common Stock ^F1	102,400	$0.00	$0.00

Holdings After Transaction: Stock Option — 135,000 contracts (Direct); Common Stock — 102,400 shares (Direct)

Footnotes (2)

F1. Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting. The RSUs vest in annual installments over a period of four years, with 1/4th of the total shares underlying the RSU vesting on each one-year anniversary of the date of grant.
F2. The stock option vests as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.

Key Figures

RSUs granted: 102,400 shares Options granted: 135,000 shares Option exercise price: $27.38 per share +3 more

6 metrics

RSUs granted 102,400 shares Restricted Stock Units of common stock granted on 2026-08-10

Options granted 135,000 shares Stock option for common stock granted on 2026-08-10

Option exercise price $27.38 per share Exercise price of the 135,000-share stock option

Option expiration 2036-08-10 Expiration date of the 135,000-share stock option

Common stock holdings after RSU grant 102,400 shares Direct common stock position reported following RSU grant

Option holdings after grant 135,000 shares Direct option position reported following option grant

Key Terms

Restricted Stock Units (RSUs), vesting, exercise price, substantially equal monthly installments

4 terms

Restricted Stock Units (RSUs) financial

"Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash"

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

vesting financial

"The RSUs vest in annual installments over a period of four years, with 1/4th"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

exercise price financial

"conversion_or_exercise_price": "27.3800""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

substantially equal monthly installments financial

"remaining shares vesting in 36 substantially equal monthly installments thereafter."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did MLYS Chief Medical Officer James J. Ferguson III receive on 2026-08-10?

James J. Ferguson III received 102,400 RSUs of common stock and a stock option for 135,000 shares at an exercise price of $27.38 per share as part of his equity compensation.

How do the 102,400 RSUs granted to the MLYS Chief Medical Officer vest?

The 102,400 RSUs vest over four years, with 1/4 of the shares vesting on each one-year anniversary of the grant date, contingent on the vesting conditions described in the award.

How many Mineralys Therapeutics (MLYS) shares does James J. Ferguson III hold after these grants?

After the reported grants, James J. Ferguson III directly holds 102,400 shares of common stock related to RSUs and a stock option for 135,000 shares, subject to the stated vesting schedules.

Were the MLYS equity awards to the Chief Medical Officer granted for cash consideration?

The RSUs were granted for no additional cash consideration, each representing a contingent right to receive one share of common stock upon vesting; the stock option has an exercise price of $27.38 per share when exercised.

What is the expiration date of the MLYS stock option granted to the Chief Medical Officer?

The stock option granted to James J. Ferguson III for 135,000 shares of Mineralys Therapeutics common stock carries an expiration date of 2036-08-10, subject to the vesting and other plan terms.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 08/12/2026 - 07:33 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ferguson James J. III

(Last)

(First)

(Middle)

150 N. RADNOR CHESTER ROAD

SUITE F200

(Street)

RADNOR

PENNSYLVANIA

19087

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Mineralys Therapeutics, Inc. [ MLYS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/10/2026		A		102,400⁽¹⁾	A	$0	102,400	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option	$27.38	08/10/2026		A		135,000		⁽²⁾	08/10/2036	Common Stock	135,000	$0	135,000	D

Explanation of Responses:

1. Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting. The RSUs vest in annual installments over a period of four years, with 1/4th of the total shares underlying the RSU vesting on each one-year anniversary of the date of grant.

2. The stock option vests as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.

Remarks:

	/s/ Jeffrey A. Munsie, attorney-in-fact	08/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR